MyMD Pharmaceuticals, Inc. stock is down -26.67% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 8.33% of the previous 15 December’s closed higher than November.
MyMD Pharmaceuticals, Inc. focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy.